Ayala Pharmaceuticals Inc (ADXS)

[Gantor50]

I have mentioned this before, but just to keep it real, most of those analyst price targets between $18-$22 are by firms that ADXS has used to underwrite their deals and offerings. So one has to consider the possibilities that there might be some Quid Pro Quo concerns there.

Outside of that, I agree that an analyst price target is not the same as total enterprise value if sold. In fact, I have seen companies sold for much higher multiples over analyst price targets, but also lower than analyst price targets.

So it can cut both ways.